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Abstract
Background: Histoplasmosis is worldwide systemic mycoses caused by the dimorphic fungus Histoplasma capsulatum.
The isolation and identification of H. capsulatum in culture is the reference test for histoplasmosis diagnosis
confirmation. However, in the absence of it, serology has been used as a presumptive diagnosis through
antibody and antigen detection. The purpose of the present study was to validate an immunoassay method
(western blot) for antibodies detection in the diagnosis of histoplasmosis.
Methods: To validate the western blot (WB) a study was conducted using 118 serum samples from patients
with histoplasmosis and 118 serum controls collected from January 2000 to December 2013 in residents of the
Rio de Janeiro State, Brazil. Diagnostic validation parameters were calculated based on the categorization of
results obtained in a 2 × 2 table and subjected to statistical analysis. In addition, the viability of deglycosylated
histoplasmin antigen (ptHMIN) onto nitrocellulose membranes previously sensitized was evaluated during the
same period.
Results: The WB test showed sensitivity of 94.9 %, specificity of 94.1 %, positive predictive value of 94.1 %,
negative predictive value of 94.9 %, accuracy of 94.5 %, and almost perfect precision. Besides, the strips have
proved to be viable for using at least 5 years after ptHMIN antigen sensitization.
Conclusion: Western blot test using ptHMIN provides sensitive, specific, and faster results. Therefore, could be
considered a useful tool in the diagnosis of histoplasmosis being used by public health system, even in situations
where laboratory facilities are relatively limited.
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Background
Histoplasmosis is a systemic disease caused by the di-
morphic fungus Histoplasma capsulatum. This disease
has a worldwide distribution and is one of the most
common respiratory mycosis, presenting endemic areas
in certain regions of the United States and Latin America
[1, 2]. In Brazil, these regions are located throughout the
country, especially in the Midwest, Northeastern and
Southeast regions [3, 4]. The infection is acquired by
inhalation of fungal infectious propagules present in or-
ganic matter rich soil, mainly with excreta of birds and
bats [1].
The clinical spectrum of this illness ranges from
asymptomatic, self-limited illness to a progressive dis-
seminated disease. Although the clinical manifestations
of histoplasmosis are well described, there is significant
overlapping of symptoms with other diseases, and the
diagnosis cannot be achieved based on clinical informa-
tion alone. [5]. Microbiological diagnosis is based on iso-
lation of the fungus in cultures, and microscopic
examination of fluids and tissues using specific staining
techniques [5]. Nonetheless, these methods have limita-
tions. Culture examination is slow, taking up to 2–4
* Correspondence: rosely.zancope@ini.fiocruz.br
1Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz,
Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, Brazil
Full list of author information is available at the end of the article
© 2016 Almeida et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Almeida et al. BMC Infectious Diseases  (2016) 16:87 
DOI 10.1186/s12879-016-1427-0
weeks, and requires level 3 biosafety facilities [6]. The
sensitivity and specificity of histopathological examin-
ation vary depending on the patient’s clinical status,
exhibiting reduced sensitivity in the subacute and
chronic forms of the pulmonary histoplasmosis [6, 7]. In
addition, the specific role of each test fluctuates accord-
ing to the clinical form, since variations in sensitivity
have been associated to different clinical presentations.
Serological methods usually have a rapid turnaround
time and detection of either antibodies or antigens can
provide information indicative of current disease. Histor-
ically the identification of antibody responses in patients
with histoplasmosis has proved useful in the diagnosis of
disease since serological evidence is the prime diagnostic
indicator of histoplasmosis [8].
Serological diagnosis for histoplasmosis focuses on the
identification of antibodies to the H [9] and/or M antigens
[10]. The two routine antibody detection methodologies
are complement fixation (CF) and immunodiffusion (ID),
because of convenience, availability, and accuracy of these
assays. In the past, CF was a popular test to diagnose
histoplasmosis but ID has been found to be more specific
[3]. The ID test qualitatively measures precipitating anti-
bodies, and is specific for the detection of antibodies to M
and H antigens, ranging from 70 to 100 % [11]. However,
it has low sensitivity, mainly in acute, disseminated and
opportunistic manifestations of the disease. In general, ID
is useful for detecting antibodies 4–6 weeks after infection
with H. capsulatum. Detection of precipitins by immuno-
diffusion is one of the most widely available techniques for
diagnosis [3], and although the presence of immunodiffu-
sion bands are less reliable than culture, anti-Histoplasma
antibodies may be detected in the serum of 90 % of pa-
tients with histoplasmosis [12]. The presence of M and H
bands is highly suggestive of active Histoplasma infection
[8]. Several enzyme-linked immunosorbent assays (ELISA)
protocols have been described for antibody detection in
histoplasmosis using diverse antigenic preparations show-
ing sensitivity among 75 to 100 % [13–16].
The reference protocols for the evaluation of the diag-
nosis of infectious diseases show that the diagnostic tar-
get must first be identified, followed by the optimization
of reagents and test used. Then, the performance of the
method should be evaluated [17]. In the past, a WB test
was developed for detection of antibodies against native
glycosylated and chemically deglycosylated M and H an-
tigens of H. capsulatum in serum obtained from patients
during the acute phase of pulmonary histoplasmosis
showing 90 and 100 % sensitivity, for the acute and
convalescent-phase respectively, and 100 % specificity
[18]. This test met the requirements of a good diagnostic
test for the acute and convalescent-phase of histoplas-
mosis. The advantage of the WB test in relation to rou-
tine serology is the identification of some cases early in
infection, before seroconversion can be detected by CF
and ID, showing a high degree of sensitivity and specifi-
city, Also, this methodology is faster and easier to realize
than those tests used in diagnostic routine. However,
these immunoassays were used only in acute and proven
histoplasmosis cases [16, 18], and it would be very im-
portant validate this methodology for diagnosis of sev-
eral forms of histoplasmosis in a large number of cases,
since it could be used in conjunction with culture to im-
prove the diagnosis of H. capsulatum infection particu-
larly in cases when microorganism isolation procedure is
negative, and also guide for the specific therapy [5].
Our aim in this study was to validate this western blot
immunoassay to detect antibodies in the serodiagnosis
of histoplamosis following the reference protocols for
the evaluation of diagnostic tests for infectious diseases
in order to determine the diagnostic accuracy of this
test. In addition, the antigenic reactivity of deglycosyl-
ated histoplasmin antigen (ptHMIN) onto nitrocellulose
membranes previously sensitized was evaluated during
the same period as a secondary objective of this study.
Methods
Target population and histoplasmosis case definition
A study was conducted in a total of 236 serum samples
collected from January 2000 to December 2013 at the
Instituto Nacional de Infectologia Evandro Chagas (INI),
Fiocruz from residents of Rio de Janeiro State without
prior treatment for histoplasmosis. The target population
was separated into two groups, histoplasmosis group and
a control group. The histoplasmosis group (n = 118) was
comprised of patients with epidemiological and clinical
history compatible with histoplasmosis. The diagnosis cri-
teria were based on a positive result in culture, or Histo-
plasma antibody detection demonstrating H or M
precipitin bands by immunodiffusion [19]. The control
group was obtained based on the proportion 1:1 case–
control, a total of 118 individuals of the same population.
The serum samples of control group were randomly ob-
tained from 40 patients with clinical suspicion of fungal
infection, but excluded of the diagnosis criteria selected,
28 patients suspected of other pulmonary mycosis (para-
coccidioidomycosis, n = 10; aspergillosis, n = 9; coccidi-
oidomycosis, n = 6; and cryptococcosis, n = 3); 10 patients
with tuberculosis; and 40 healthy blood donors (Fig. 1).
The definition of histoplasmosis was based on the
consensus EORT/MSG [20], and the clinical forms
followed recommendations [7, 21]. Proven histoplasmo-
sis included individuals with identification of H. capsula-
tum yeasts in cultures or histopathological analyzes.
Positive ID combined with clinical and radiologic find-
ings were required for classification of probable disease.
All individuals included in the study were probed to
Almeida et al. BMC Infectious Diseases  (2016) 16:87 Page 2 of 8
detect antibodies against H. capsulatum by WB and ID
tests.
Study design
This is a retrospective study based on standard clinical,
laboratorial and epidemiological dates collected in the
medical records of INI/Fiocruz.
The variable analyzed were age, gender, comorbidity
(AIDS, tuberculosis), specific laboratory tests as serology
by ID, mycological tests and clinical form of illness.
Clinical and laboratory data were collected by an inde-
pendent investigator, blinded to clinical information.
Ethical statement
This study was approved by the Research Ethics Commit-
tee of the Instituto Nacional de Infectologia Evandro
Chagas, Fiocruz, accession number 19109913.0.0000.5262.
Serologic tests and antigens
ID tests to detect antibodies to histoplasmin (HMIN),
paracoccidioidin and Aspergillus fumigatus antigen were
performed on serum specimens obtained from all indi-
viduals enrolled in this study [22]. HMIN was produced
from mycelium-form cultures of H. capsulatum IGS 4/5
(INCQS 70308) as described previously [23], and H and
M antigens were chromatographically purified [24].
Chemical deglycosylation was achieved according to pre-
viously studies [25, 26]. Briefly, sodium meta-periodate
(NaIO4) was added to 2-ml aliquots of purified antigens
to a final concentration of 100 mM. After incubation for
18 h at 4 °C in the dark, residual periodate was
consumed by incubation for 15 min with an equimolar
amount of glycerol, followed by addition of 1 M sodium
borohydride. After incubation for 2 h at 4 °C, the reac-
tion mixture was dialyzed against cold deionized water.
Western blot (WB) immunoassay
Native and deglycosylated antigens were analyzed by so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), on 10 % polyacrylamide resolving gels with
a 4 % polyacrylamide staking gel. The gels were then
processed for western blot performed according to the
protocol previously established [18]. Briefly, after electro
transfer of proteins (16.75 ug) to nitrocellulose mem-
branes in a Mini Trans Blot cell (Bio-Rad), membranes
were sliced vertically, and free binding sites in the mem-
branes were blocked by incubation for 60 min in 5 %
(wt/vol) nonfat milk in 20 mM Tris–HCl–500 mM
NaCl–0.2 % Tween 20 (pH 7.5) (TTBS). Next, strips
were incubated for 60 min at room temperature with
serum specimens diluted 1:100 in TTBS containing 5 %
nonfat milk. Strips were washed in TTBS three times for
five minutes each; and then goat anti-human immuno-
globulin G (IgG)-alkaline phosphatase conjugates (Jackson
ImmunoResearch, EUA) diluted in TTBS (1:3.000) were
added and incubated as described above. Following in-
cubation, blot strips were washed and incubated with
substrate solution consisting of 5-bromo-4-chloro-3-
indolylphosphate (BCIP; 15 mg/ml in dimethylformamide
[DMF]) and nitroblue tetrazolium (NBT; 30 mg/ml in
70 % aqueous DMF). Substrate stock solutions were
diluted 1:100 before use in Tris/NaCl buffer (100 mM
Total of histoplasmosis cases 
selected between 2000-2013  
(n=195):
Excluded samples:
Duplicate samples: n= 77         








Fig. 1 Serum samples tested during validation Western blot immunoassay for diagnosis of histoplasmosis
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Tris–HCl [pH 9.5], 100 mM NaCl, 50 mM MgCl2). After
color development strips were rinsed exhaustively in
deionized water.
Two experienced investigators with longstanding ex-
perience in the WB performed the analysis in the an-
onymous sera, blindly with regard to the clinical and
laboratorial findings. The samples were identified with
sequential numbering by a third investigator avoiding
the identification of cases and controls by the executors
of the analysis. The immunoassays were then carried out
separately for each of the two investigators, including all
steps of the methodology. The test was repeated three
times with readings performed by two investigators in
order to evaluate the intra and interobserver agreement
index.
Western blot performance characteristics
To calculate the performance characteristics of the test,
the true-positive (TP), false-positive (FP), false-negative
(FN), and true-negative (TN) results were analyzed [27].
Analysis of the membranes
Nitrocellulose membranes previously sensitized with the
antigen ptHMIN, lot # Hc05 were maintained at room
temperature and tested progressively for the antigenic
reactivity over the time periods of 1 day, 1 month, 6
months, 1, 2, 3, 4 and 5 years, by WB with serum sample
(#20965) obtained from a proven histoplasmosis case to
assess the viability of the membranes containing
ptHMIN, respecting the conditions listed above.
Statistical analysis
The epidemiological and laboratorial data were evaluated
by bivariate analysis using Chi-squared test or Fisher
exact test if any value in the cells of the contingency
table was less than five. Results were considered statisti-
cally significant when p < 0.05. The diagnostic accuracy
of the WB was evaluated by sensitivity, specificity, pre-
dictive values and likelihood ratios, with ranges of 95 %
confidence intervals (CI). The reproducibility of the test
was calculated and classified using agreement index by
Kappa coefficient according to Landis & Koch (1977)
[28]. In addition, we used odds ratio (OR) to measure
the presence of H and M bands simultaneously in the
laboratorial tests applied in this study. All data were sub-
jected to statistical analysis by using of Statistical Pack-
age for Social Sciences SPSS software, version 16.0.
Results
Baseline characteristics of patients
Between January 2000 and December 2013, 118 cases of
histoplasmosis were diagnosed in the Instituto Nacional
de Infectologia Evandro Chagas, and could be filled on
the criteria of inclusion for this study (Fig. 1). The mean
age of all patients (cases and controls) was 41.5 years
(10-81 years), 75.4 % of the patients were male and
24.6 % female. Among this population, 37.3 % were
HIV-patients (Table 1).
The clinical form most commonly found in all patients
with histoplasmosis was pulmonary (50.8 %), followed by
disseminated (36.5 %) and mediastinal histoplasmosis
(4.2 %). Fifty-four patients had proven histoplasmosis. In
the proven cases of histoplasmosis the pathogen was ob-
tained by culture isolation in 60 clinical samples such as
bone marrow (n = 15), respiratory secretion (n = 14), skin
lesions (n = 9), blood (n = 8), mucosal lesions (n = 8) and
lymph node aspirate (n = 6). It must be emphasized that
six patients had the fungus isolated from two different
clinical samples. In addition, sixty-four were classified as
probable histoplasmosis (40 acute pulmonary, 6 chronic
pulmonary, 5 disseminated, 3 mediastinal, and 10 non-
defined clinical and serological suspected cases who
could not be classified in none of the preceding forms)
[7, 21] based on the presence of M and/or H bands in
immunodiffusion in conjunction with clinical and radio-
logic findings.
Immunodiffusion test
All the samples from patients with histoplasmosis were
re-tested by ID for the detection of anti-H. capsulatum
antibodies. Of 118 sera from patients with histoplasmo-
sis, 103 (87.3 %) had reactivity, characterized by the
presence of at least one line of precipitation. Fifteen
samples (12.7 %) were negative. The results were compared
with those performed immediately after blood collection,
demonstrating excellent agreement (Kappa = 0.96). None of
Table 1 Baseline characteristics histoplasmosis cases (n = 118)
and control group (n = 118)
Variables Cases n° (%) Controls n° (%) p value**
Sex
Men 89 (75.4) 90 (76.3) 1.000
Woman 29 (24.6) 28 (23.7)
Age (years)
<40 57 (48.3) 51 (43.2) 0.513
≥40 61 (12.7) 67 (11.0)
HIV status
Positive 44 (37.3) 22 (18.6) 0.002
Negative 21 (17.8) 59 (50.0)
Non-tested 53 (44.9) 37 (31.4)
Tuberculosisa
Present 20 (16.9) 17 (14.4) 0.720
Absent 43 (36.4) 30 (25.4)
Missing 55 (46.6) 71 (60.2)
aDiagnosis by isolation of Mycobacterium tuberculosis in sample of various
clinical specimens; **p value < 0.05
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the 118 control sera that were probed for histoplasmosis,
paracoccidioidomycosis, and aspergillosis, were prior posi-
tive by this method.
Western blot
Any well-defined band, with molecular weight of 115
and 88 kDa represent the specific antibodies against H
and M antigen, respectively (Fig. 2). H and M bands
were identified in sera of 47 patients with histoplasmosis
(39.8 %). In 65 samples (55.1 %) it was verified just the
M band and in six patients (5.1 %) no band was
identified.
Diagnostic Accuracy of the WB for anti-H. capsulatum
antibodies detection
The analysis of 118 serum samples from proven and
“probable histoplasmosis” showed that 112 were cor-
rectly classified as true-positive samples and only six
samples had false-negative results. These samples were
from HIV-patients with disseminated histoplasmosis. Of
the 118 control samples, false-positive results were ob-
served in seven samples. Cross-reactivity has seen in sera
from patients with paracoccidioidomycosis (5), aspergil-
losis (1) and tuberculosis (1).
The results of the diagnostic accuracy and their confi-
dence intervals are shown in Table 2. The WB had a
sensitivity of 94.9 % (95 % CI: 92.1 to 97.7 %), a specifi-
city of 94.1 % (95 % CI: 91.1 to 97.1 %), an accuracy of
94.5 % (95 % CI: 91.6 to 97.4 %), a positive predictive
value (PPV) of 94.1 % (95 % CI: 91.1 to 97.1 %), and a
negative predictive value (NPV) of 94.9 % (95 % CI: 92.1
to 97.7 %).
The reproducibility of the test has shown that the
intraobserver and interobserver agreement (Kappa = 0.99
and 0.96, respectively) were classified as almost perfect.
Differently from ID; where both H and M precipitin
bands were observed just in 8.9 % of the positive sam-
ples tested, in WB the H and M were detected simultan-
eously in 42.0 % of samples, showing a gain in sensitivity
(Table 3).
Analysis of the membranes
The evaluation of the viability of previously sensitized
nitrocellulose membranes with the antigen ptHMIN was
performed by WB probed against the serum sample #
20965 from proven histoplasmosis patient. It was dem-
onstrated reactivity on the membranes up to 5 years
(Fig. 2).
Discussion
The definitive diagnosis of histoplasmosis is usually
based on the isolation and identification of the H. capsu-
latum in cultures or by identification of fungi in bio-
logical samples with special staining [7, 29]. However,
this process is time-consuming and has limitations in
sensitivity [30], mainly in acute and disseminated histo-
plasmosis that need be rapidly diagnosed for the prompt
initiation of therapy [31].
Presently, there are additional diagnostic tools avail-
able for diagnosis of histoplasmosis to supplement cul-
ture and microscopic examination. These laboratory
tests have a rapid turnaround time and reasonable speci-
ficity and sensitivity. For instance, serological techniques
involving antibody and antigen detection have been de-
veloped using different methodologies. Immunoassays
for antibody detection using ptHMIN, has played an im-
portant role in the diagnosis of histoplasmosis showing
high sensitivity and specificity for diagnosis of histoplas-
mosis. Nevertheless, these immunoassays were used only
in acute forms and proven histoplasmosis cases [16, 18].
In the past, a WB test was developed for detection of
antibodies against native glycosylated and chemically de-
glycosylated M and H antigens of H. capsulatum in
serum obtained from patients during the acute phase of
pulmonary histoplasmosis showing 90 and 100 %
Fig. 2 Analysis of the viability of membranes. Lanes MW- Molecular
weight; 1- One day; 2- One month; 3- Six months; 4- One year; 5- Two
years; 6- Three years; 7- Four years; 8- Five years; 9- Healthy individual
(negative control)
Table 2 Serological parameters for the Western blot using
ptHMIN






Positive likelihood ratios 16.0 -
Negative likelihood ratios 0.1 -
a(CI) confidence interval; b(PPV) positive predictive value; c(NPV), negative
predictive value
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sensitivity, for the acute and convalescent-phase respect-
ively, and 100 % specificity [18]. These results can be
compared with the values of sensitivity (94.4 %) and spe-
cificity (94.1 %) obtained in this study. However, in the
latter it was evaluated serum samples from other clinical
forms of histoplasmosis as well from individuals with
other fungal infections, with tuberculosis besides healthy
individuals, which could explain the small differences
found in the sensitivity and specificity parameters. In
addition, the results presented here demonstrate the util-
ity of this methodology in the diagnosis of histoplasmo-
sis through more robust evaluation in different
populations being faster than those test used in diagnos-
tic routine, and should be applied in microbiology la-
boratories since has almost perfect reproducibility,
producing repeated and consistent results.
The WB evaluated here showed to be an excellent
diagnostic test for histoplasmosis since it fits all criteria
suggested by international guides for accuracy in test-
ing such as high sensitivity and specificity; ease to use
and storage [17, 32]. Then, this is the first description
about WB validation using ptHMIN for diagnosis of
several forms of histoplasmosis in a large number of
cases. Serological histoplasmosis diagnosis is focused
on the identification of anti-H and anti-M antibodies
by ID and the presence of both the H and M precipitins
in a serum sample is considered to be conclusive for
the diagnosis of this mycoses [3]. However, the M band
is mostly found in acute and chronic forms of histo-
plasmosis. This band persists for months to years after
the infection has resolved [30], and the H band is
present only in 7.0 % of sera from patients with acute
histoplasmosis, and rarely can be found without M
band. The presence of H band is indicative of chronic
or severe acute forms of histoplasmosis [33]. In this
study, the presence of both anti-M and anti-H anti-
bodies was more frequently observed in WB than ID, in
both proven and probable cases of histoplasmosis due
the higher sensitivity of primary binding assays, such as
ELISAs and western blot than precipitin tests, and
mainly for the inactivation of carbohydrate epitopes
present in our antigenic preparation that led to in-
creased WB test sensitivity [18, 26]. WB could be useful
as conclusive method of laboratorial diagnosis of this
mycosis.
Although, the WB showed a high sensitivity, false
negative results were found in six HIV-patients with
confirmed disseminated histoplasmosis. This mycosis
usually occurs in HIV-patients that have advanced im-
munosuppression [34, 35]. Probably, the absence of de-
tectable antibodies may be associated with this event.
The time of serum collection is also an important vari-
able in the detection of antibodies in histoplasmosis
since anti-M and anti-H antibodies are detected between
2 and 6 weeks, and posteriorly formation of immune
complexes [30].
Reactivity against the M band (88 kDa), was also ob-
served in 7 false-positive serum samples; five sera from
patients with paracoccidiodomycosis, one with aspergil-
losis, and one with tuberculosis, similar to previously re-
sults [18]. However, antibodies against M band can
persist for long time after disease resolution [3] without
clinical manifestations compatible with histoplasmosis.
For instance, in individuals from endemic areas, such as
Rio de Janeiro state, the presence of these antibodies can
represent only previous exposition to H. capsulatum. In
these cases, the results should be carefully interpreted,
and in this way, does not lead to a mistaken diagnosis of
histoplasmosis in patients affected with other infectious
diseases [33]. However, the association of clinical and
epidemiological data with the laboratory evidences ad-
dress in favor of the reliability of the test. In addition,
co-infections with other fungal infections or granuloma-
tous lung diseases such as tuberculosis may coexist in
these patients [36]. This event also may usually occur in
individuals with severe immunosuppression or in those
that suffer of other pulmonary disease [37, 38].
The accuracy is an essential parameter for the valid-
ation of a diagnostic test, and it is characterized by re-
producibility measurements of the test. In this study we
observed intra- and interobserver agreement in the WB
test, which classify the test as almost perfect, making it
possible to be applied in multicenter studies.
It has been demonstrated that nitrocellulose mem-
brane is optimal for transfer and subsequent binding of
specific proteins. We previously demonstrated that west-
ern blot using nitrocellulose membranes probed with
ptHMIN was an excellent method to detect antibodies
in patients infected with H. capsulatum [18, 25, 26].
However, up to date, there is not information about the
Table 3 Performance results of serological tests for detection of antibodies against Histoplasma capsulatum
Histoplasmosis Immunodifusion (ID)a Western blot (WB)a p-value** OR
H and M bands M band H and M bands M band
Proven (n = 54) 8 36 21 27 0.009 3.88
Provable (n = 64) 2 62 26 38 0.000 21.21
Total (n = 118) 10 98 47 65 0.000 7.08
aCases non reagent: ID – 10 cases; WB – 6 cases; **p-value < 0.05 (Chi-square Test and Fisher Exact Test)
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time that the nitrocellulose membranes, sensitized with
ptHMIN antigen, can remain viable and without struc-
tural damage for the use in WB [18, 25, 26]. Our study
demonstrated that WB sensitized strips may be stored at
room temperature up to 5 years, presenting reactivity in
WB without compromising test quality. With this, there
is a potential for pre-manufactured blot strips to simplify
test performance, permitting the distribution to other la-
boratories in order to promote a worldwide multicenter
evaluation.
Future studies of WB validation will be conducted in
different Brazilian regions in order to evaluate a large
number of samples. Furthermore, additional evaluation
of this assay is needed to better characterize its clinical
sensitivity in untreated and treated patients, the kinetics
of antibody clearance as measured by this test, and the
ability of antibody tests in general to predict treatment
success or failure, mainly in the acute form of histoplas-
mosis. Importantly, the validated test is simple to per-
form, requiring only a basic lab infrastructure for its
realization. This method can be performed by any pro-
fessional, if properly trained and special attention should
be given to reading the test result.
Conclusion
The WB for diagnosis of histoplasmosis, using ptHMIN
antigen, showed that this method can be considered a
useful tool in the diagnosis of histoplasmosis being used
by public health system, even in situations where labora-
tory facilities are relatively limited. In addition, WB is
faster than those test used in diagnostic routine, and
should be applied in microbiology laboratories since has
almost perfect reproducibility, producing repeated and
consistent results. Cost evaluations are necessary to
completely define the role of this technique on large
scale. As future perspective, multicenter trials should be
held involving laboratories from other Brazilian regions
or even other countries engaged in the diagnosis of this
mycosis.
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